BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 100 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,744,000 | -26.1% | 1,800,000 | -26.5% | 1.80% | -29.2% |
| Q2 2023 | $17,248,000 | +29.3% | 2,450,000 | +53.1% | 2.54% | +27.7% |
| Q1 2023 | $13,344,000 | -19.8% | 1,600,000 | +10.3% | 1.99% | -17.8% |
| Q4 2022 | $16,646,000 | +10.1% | 1,450,000 | +20.8% | 2.42% | +30.4% |
| Q3 2022 | $15,120,000 | +19.1% | 1,200,000 | 0.0% | 1.85% | -3.7% |
| Q2 2022 | $12,696,000 | +939.8% | 1,200,000 | +179.1% | 1.93% | +254.0% |
| Q2 2016 | $1,221,000 | +0.3% | 430,000 | 0.0% | 0.54% | -1.8% |
| Q1 2016 | $1,217,000 | – | 430,000 | – | 0.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |